TD Cowen downgraded Inozyme (INZY) to Hold from Buy with a $4 price target after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment
- Inozyme downgraded to Neutral from Overweight at Piper Sandler
- Inozyme downgraded to Hold from Buy at Jefferies
- Leerink bullish on BioMarin following Inozyme deal, expects additional BD
- Inozyme downgraded to Market Perform from Outperform at Raymond James